Appili Therapeutics Stock Z Score
| APLI Stock | CAD 0.02 0.01 20.00% |
What is Altman Z-Score?
The Altman Z-Score is one of the most widely-used financial formulas to predict bankruptcy risk. Developed by Edward Altman in 1968, this model combines five key financial ratios to generate a single score that indicates the likelihood of financial distress within two years.
How to Interpret Appili Therapeutics Z-Score
Z-Score above 3.0: Safe zone - Low bankruptcy risk
Z-Score 2.7 - 3.0: Gray zone - Moderate risk
Z-Score 1.8 - 2.7: Warning zone - Elevated risk
Z-Score below 1.8: Distress zone - High bankruptcy risk
Why Appili Therapeutics Z-Score Matters
Investors use the Z-Score to assess financial health before making investment decisions. A declining Z-Score over time may signal deteriorating fundamentals, while an improving score suggests strengthening financial position. The model evaluates five critical metrics: working capital to assets, retained earnings to assets, EBIT to assets, market value of equity to total liabilities, and sales to assets.
Appili Therapeutics Z-Score Analysis
The module uses available fundamental data of Appili Therapeutics to calculate the Altman Z score based on five fundamental metrics from the company's most recent public disclosure documents. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Appili Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation.
Appili | Z Score |
Appili Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Appili Therapeutics is extremely important. It helps to project a fair market value of Appili Stock properly, considering its historical fundamentals such as Z Score. Since Appili Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Appili Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Appili Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Appili Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Appili Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Appili Therapeutics.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Appili Therapeutics on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Appili Therapeutics or generate 0.0% return on investment in Appili Therapeutics over 90 days. Appili Therapeutics is related to or competes with XORTX Therapeutics, and Aptose Biosciences. Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for... More
Appili Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Appili Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Appili Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 20.57 | |||
| Information Ratio | 0.0631 | |||
| Maximum Drawdown | 45.0 | |||
| Value At Risk | (20.00) | |||
| Potential Upside | 25.0 |
Appili Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Appili Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Appili Therapeutics' standard deviation. In reality, there are many statistical measures that can use Appili Therapeutics historical prices to predict the future Appili Therapeutics' volatility.| Risk Adjusted Performance | 0.0644 | |||
| Jensen Alpha | 0.9148 | |||
| Total Risk Alpha | (0.1) | |||
| Sortino Ratio | 0.0432 | |||
| Treynor Ratio | 1.64 |
Appili Therapeutics February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0644 | |||
| Market Risk Adjusted Performance | 1.65 | |||
| Mean Deviation | 9.32 | |||
| Semi Deviation | 9.83 | |||
| Downside Deviation | 20.57 | |||
| Coefficient Of Variation | 1469.05 | |||
| Standard Deviation | 14.1 | |||
| Variance | 198.72 | |||
| Information Ratio | 0.0631 | |||
| Jensen Alpha | 0.9148 | |||
| Total Risk Alpha | (0.1) | |||
| Sortino Ratio | 0.0432 | |||
| Treynor Ratio | 1.64 | |||
| Maximum Drawdown | 45.0 | |||
| Value At Risk | (20.00) | |||
| Potential Upside | 25.0 | |||
| Downside Variance | 423.15 | |||
| Semi Variance | 96.67 | |||
| Expected Short fall | (24.62) | |||
| Skewness | 0.3264 | |||
| Kurtosis | (0.34) |
Appili Therapeutics Backtested Returns
Appili Therapeutics appears to be out of control, given 3 months investment horizon. Appili Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0395, which signifies that the company had a 0.0395 % return per unit of risk over the last 3 months. By analyzing Appili Therapeutics' technical indicators, you can evaluate if the expected return of 0.54% is justified by implied risk. Please makes use of Appili Therapeutics' Risk Adjusted Performance of 0.0644, downside deviation of 20.57, and Mean Deviation of 9.32 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Appili Therapeutics holds a performance score of 3. The firm shows a Beta (market volatility) of 0.58, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Appili Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Appili Therapeutics is expected to be smaller as well. Please check Appili Therapeutics' standard deviation, total risk alpha, treynor ratio, as well as the relationship between the jensen alpha and sortino ratio , to make a quick decision on whether Appili Therapeutics' price patterns will revert.
Auto-correlation | 0.09 |
Virtually no predictability
Appili Therapeutics has virtually no predictability. Overlapping area represents the amount of predictability between Appili Therapeutics time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Appili Therapeutics price movement. The serial correlation of 0.09 indicates that less than 9.0% of current Appili Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.09 | |
| Spearman Rank Test | 0.19 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
In accordance with the company's disclosures, Appili Therapeutics has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all Canada stocks is 100.0% higher than that of the company.
Appili Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Appili Therapeutics from analyzing Appili Therapeutics' financial statements. These drivers represent accounts that assess Appili Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Appili Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 65.7M | 8.0M | 4.5M | 4.2M | 4.9M | 4.6M | |
| Enterprise Value | 6.3M | 9.7M | 12.3M | 15.3M | 17.6M | 21.8M |
Appili Fundamentals
| Return On Equity | -9.39 | ||||
| Return On Asset | -2.69 | ||||
| Operating Margin | (88.64) % | ||||
| Current Valuation | 14.3 M | ||||
| Shares Outstanding | 121.27 M | ||||
| Shares Owned By Insiders | 0.06 % | ||||
| Shares Owned By Institutions | 11.84 % | ||||
| Number Of Shares Shorted | 5.98 K | ||||
| Price To Book | 1.40 X | ||||
| Price To Sales | 11.76 X | ||||
| Revenue | 100.44 K | ||||
| Gross Profit | 100.44 K | ||||
| EBITDA | 360.57 K | ||||
| Net Income | (2.62 M) | ||||
| Cash And Equivalents | 5.55 M | ||||
| Cash Per Share | 0.05 X | ||||
| Total Debt | 12.29 M | ||||
| Current Ratio | 1.99 X | ||||
| Book Value Per Share | (0.12) X | ||||
| Cash Flow From Operations | 868.82 K | ||||
| Short Ratio | 0.01 X | ||||
| Earnings Per Share | (0.02) X | ||||
| Target Price | 0.15 | ||||
| Beta | 0.13 | ||||
| Market Capitalization | 3.03 M | ||||
| Total Asset | 3.03 M | ||||
| Retained Earnings | (71.72 M) | ||||
| Working Capital | (12.68 M) | ||||
| Net Asset | 3.03 M |
About Appili Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Appili Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Appili Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Appili Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Appili Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Appili Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Appili Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Appili Stock
| 0.42 | ETG | Entree Resources | PairCorr |
| 0.39 | NICU | Magna Mining | PairCorr |
| 0.35 | AIM | Aimia Inc | PairCorr |
| 0.35 | CU-PH | Canadian Utilities | PairCorr |
| 0.33 | RKR | ROKMASTER Resources Corp | PairCorr |
The ability to find closely correlated positions to Appili Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Appili Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Appili Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Appili Therapeutics to buy it.
The correlation of Appili Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Appili Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Appili Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Appili Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Appili Stock
Appili Therapeutics financial ratios help investors to determine whether Appili Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Appili with respect to the benefits of owning Appili Therapeutics security.